Komori
JCR Pharmaceuticals (4552) · InitiativeAchieved

Issuance of Share Acquisition Rights for Directors and Executive Officers

First written in FY2018-Q2. 7 of 11 entries say "Advanced", first in FY2019-Q3. Latest entry: 2026-07-22.

11entries
10years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2018-Q2AdvancedFY2019-Q3 – FY2024-Q2AchievedFY2025-H1 – 2026-07-222017: 12018: 020182019: 220192020: 120202021: 120212022: 120222023: 120232024: 220242025: 020252026: 22026
Same theme, other companies
Discontinuation of Share-Based Compensation Stock Options and Transition to Restricted Stock CompensationA theme 37 companies write about · 0 as a headwind · 39 as a tailwind

7 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1AchievedAnnual report

    「The company resolved as set out below to dispose of treasury shares as restricted stock compensation for its directors, executive officers who do not concurrently serve as directors, and employees. Payment date: 22 August 2024 Class and number of shares to be disposed of: the company's common shares, 663,500 shares」

    Following the change from the previous stock options in the form of share-based compensation to restricted stock compensation, the company disposed of 663,500 treasury shares on 22 August 2024.
  2. FY2024ReframedAnnual report

    「Following the resolution at the 49th Annual General Meeting of Shareholders held on 26 June 2024 to grant restricted stock as compensation and other remuneration to directors, including outside directors, the company abolished the provision on the amount of compensation and other remuneration relating to stock acquisition rights as stock options in the form of share-based compensation for directors other than outside directors, which had been approved at the 48th Annual General Meeting of Shareholders held on 21 June 2023.」

    The company changed its system of share-based compensation for officers from the previous stock options in the form of share-based compensation to restricted stock compensation, and also resolved to adopt the alternative measure of having holders waive unexercised stock acquisition rights.
  3. FY2024-Q2AdvancedAnnual report

    「2023 First Stock Acquisition Rights (issued on 12 July 2023) Eligible recipients and number of recipients: 5 directors, 6 executive officers and others Number of stock acquisition rights: 710 Number of shares underlying the stock acquisition rights: 71,000 shares Exercise period: from 12 July 2023 to 11 July 2053」

    The company issued 710 stock acquisition rights, representing 71,000 underlying shares, to 5 directors and 6 executive officers and others.
  4. FY2023-Q2AdvancedAnnual report

    「2022 First Stock Acquisition Rights (issued on 12 July 2022) Eligible recipients and number of recipients: 5 directors, 4 executive officers Number of stock acquisition rights: 785 Number of shares underlying the stock acquisition rights: 78,500 shares Exercise period: from 12 July 2022 to 11 July 2052」

    The company issued 785 stock acquisition rights, representing 78,500 underlying shares, to 5 directors and 4 executive officers.
  5. FY2022-Q2AdvancedAnnual report

    「2021 First Stock Acquisition Rights (issued on 13 July 2021) Eligible recipients and number of recipients: 5 directors, 4 executive officers Number of stock acquisition rights: 540 Number of shares underlying the stock acquisition rights: 54,000 shares Exercise period: from 13 July 2021 to 12 July 2051」

    The company issued 540 stock acquisition rights, representing 54,000 underlying shares, to 5 directors and 4 executive officers.
  6. FY2021-Q2AdvancedAnnual report

    「2020 First Stock Acquisition Rights (issued on 14 July 2020) Eligible recipients and number of recipients: 5 directors, 1 subsidiary director, 4 executive officers Number of stock acquisition rights: 155 Number of shares underlying the stock acquisition rights: 15,500 shares Exercise period: from 14 July 2020 to 13 July 2050」

    The company newly issued 155 stock acquisition rights, representing 15,500 underlying shares, to directors, subsidiary directors and executive officers.
  7. FY2020-Q2AdvancedAnnual report

    「2019 First Stock Acquisition Rights (issued on 12 July 2019) Eligible recipients and number of recipients: 5 directors, 1 subsidiary director, 7 executive officers Number of stock acquisition rights: 275 Number of shares underlying the stock acquisition rights: 27,500 shares Exercise period: from 12 July 2019 to 11 July 2049」

    The company newly issued 275 stock acquisition rights, representing 27,500 underlying shares, to directors, subsidiary directors and executive officers.
  8. FY2019-Q3AdvancedAnnual report

    「2018 First Stock Acquisition Rights (issued on 9 November 2018) Number of stock acquisition rights: 270 Number of shares underlying the stock acquisition rights: 27,000 shares (Note 2) Exercise period: from 9 November 2018 to 8 November 2048」

    The company issued 270 2018 First Stock Acquisition Rights, apparently for directors and executive officers, representing 27,000 underlying shares. The exercise period runs from 9 November 2018 to 8 November 2048.
  9. FY2018-Q2First statedAnnual report

    「First Series of Stock Acquisition Rights for fiscal 2017 (issued 14 July 2017); number of stock acquisition rights 290; number of shares underlying stock acquisition rights 29,000; exercise period from 14 July 2017 to 13 July 2047」

    On 14 July 2017, the company issued 290 stock acquisition rights covering 29,000 shares to directors and executive officers.
Moved together

"Approval and Application Milestones for the Development Pipeline" moved the same way as this thread, in the same document, in 7 of its 11 moves.

775444★123456
  1. ★This thread
  2. 1Approval and Application Milestones for the Development Pipeline7×
  3. 2Expanding revenue from core products and strengthening the product portfolio7×
  4. 3Commercialization, Joint Research and Licensing of J-Brain Cargo®5×
  5. 4Development into a research-driven company with a strong global presence4×
  6. 5Expansion of International Partnering, Technology Licensing and API Supply4×
  7. 6Strengthening Business Development and Licensing Operations Leveraging Proprietary Technologies4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the Share Issuance and Disposal of 2026-07-22: "Achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Issuance of Share Acquisition Rights for Directors and Executive Officers | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori